Edgewise Therapeutics: Funding, Investors & Team (Sep 2026)
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.
Edgewise Therapeutics has raised $138M across 1 funding round on record, the most recent a Post-IPO Equity of $138M announced in Sep 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Edgewise Therapeutics Company Profile and Key Stats
Latest funding round on record: Sep 2022.
Edgewise Therapeutics Funding Rounds
Edgewise Therapeutics Founders and Leadership Team
Contact details for the Edgewise Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Edgewise Therapeutics Funding Compared to Other Biotechnology Startups
Edgewise Therapeutics' latest round of $138M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Edgewise Therapeutics in Biotechnology and Boulder
Companies Similar to Edgewise Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Edgewise Therapeutics Funding FAQs
What does Edgewise Therapeutics do?
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.
How much funding has Edgewise Therapeutics raised?
Edgewise Therapeutics has raised $138M across 1 round on record. The most recent is a Post-IPO Equity of $138M announced in Sep 2022.
When did Edgewise Therapeutics last raise funding?
Edgewise Therapeutics' most recent funding round on record is a Post-IPO Equity of $138M, announced in Sep 2022.
Who founded Edgewise Therapeutics?
FundedIQ lists Alan Russell (Founder) at Edgewise Therapeutics.
Where is Edgewise Therapeutics headquartered?
Edgewise Therapeutics is based in Boulder, Colorado, United States.
How many employees does Edgewise Therapeutics have?
Edgewise Therapeutics is in the 51-100 employee band.
How does Edgewise Therapeutics' funding compare to other Biotechnology startups?
Edgewise Therapeutics' latest round of $138M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Edgewise Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Edgewise Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.